Acute myopericarditis as the initial manifestation of an adult-onset Still’s disease flare
DOI:
https://doi.org/10.32818/reccmi.a11n2a7Keywords:
adult-onset Still’s disease, myopericarditis, hyperferritinemia, exanthema, procalcitoninAbstract
Adult-onset Still’s disease (AOSD) is a rare systemic autoinflammatory disorder. We present the case of a 30-year old man who initially presented with acute myopericarditis with severe biventricular dysfunction, accompanied by a generalized elevation of proinflammatory markers, extreme hyperferritinemia, and an atypical skin rash. After infectious and autoimmune etiologies were ruled out, he was diagnosed with an AOSD flare and treatment with corticosteroids and immunomodulatory therapy was started, with prompt clinical improvement. This case is notable for its initial presentation, given the rarity of myocardial involvement as the first manifestation of the disease, and highlights the importance of correctly interpreting inflammatory markers within the patient’s clinical course and overall context.
Downloads
Metrics
References
Bindoli S, Baggio C, Doria A, Sfriso P. Adult-onset Still’s disease (AOSD): advances in understanding pathophysiology, genetics and emerging treatment options. Drugs. 2024; 84: 257-274. doi: https://doi.org/10.1007/ s40265-024-01993-x (último acceso ago. 2026). DOI: https://doi.org/10.1007/s40265-024-01993-x
Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheu-matol. 1992; 19(3): 424-430.
Horna N M, Romero R, Larrauri C, Córdova F, Martín Mispireta J, Alarcón J. Miocardiopericarditis en la enfermedad de Still del adulto. Arch Peru Cardiol Cir Cardiovasc. 2023; 1(3): 194-97. doi: https://doi.org/10.47487/apcyccv. v1i3.65 (último acceso ago. 2026). DOI: https://doi.org/10.47487/apcyccv
Yıldırım R, Oğuzman S, Dinler M, Üsküdar Cansu D, Korkmaz C. Procalcitonin can increase during activation of adult-onset Still’s disease (AOSD) in the absence of an infection focus. Rheumatology. 2023;62(4): e109-e110. doi: https://doi.org/10.1093/rheumatology/keac511 (último acceso ago. 2026). DOI: https://doi.org/10.1093/rheumatology/keac511
Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-onset still disease manifestations, treatment, outcome, and prog-nostic factors in 57 patients. Medicine (Baltimore). 2014; 93(2): 91-99. doi: https://doi.org/10.1097/MD.0000000000000021 (último acceso ago. 2026). DOI: https://doi.org/10.1097/MD.0000000000000021
Ruscitti P, Di Cola I, Vitale A, Caggiano V, Palumbo P, Di Cesare E, et al. International AIDA Network and the Autoinflammatory Diseases Working Group of the Italian Society of Rheumatology. evaluation of myocarditis in patients with still disease: clinical findings from the Multicenter International AIDA Network Still Disease Registry. J Rheumatol. 2025; 52(3): 226-233. doi: https://doi.org/10.3899/jrheum.2024-0683 (último acceso ago. 2026). DOI: https://doi.org/10.3899/jrheum.2024-0683
Narváez J, Palacios-Olid J, García de Yebenes MJ, Holgado S, Olivé A, Casafont-Solé I, et al. Non-classical complications of adult-onset Still's disease: a multicenter spanish study. J Clin Med. 2025; 14(1): 285. doi: https://doi. org/10.3390/jcm14010285 (último acceso ago. 2026). DOI: https://doi.org/10.3390/jcm14010285
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Teresa Romeo Allepuz, Berta María Mañas Lorente, Ana Carmen Huertas Puyuelo, Cristina García-Domínguez, Eva Sampedro Calavia, Miriam Royo Álvarez
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
